Skip to main content

Table 4 Anti-obesity drugs currently approved for use in at least one country

From: Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review

Brand name Active ingredient Mechanism of action Year approved
Adipex-P, Ionamin Phentermine Precise mechanism unknown: norepinephrine-dopamine releasing agent 1959
Alli, Xenicala Orlistat Inhibits gastric and pancreatic lipases 1999
Belviqa Lorcaserin Selective 5-HT2C receptor agonist 2012
Contrave, Mysimbaa Naltrexone + bupropion Bupropion: re-uptake inhibitor and releasing agent of norepinephrine and a nicotinic acetylcholine receptor antagonist; naltrexone augments bupropion’s activation of proopiomelanocortin (POMC) 2014
Didrex Benzphetamine Precise mechanism unknown: norepinephrine-dopamine releasing agent 1960
Obezine Phendimetrazine Precise mechanism unknown: norepinephrine-dopamine releasing agent 1961
Qsymia, Qnexaa Phentermine + topiramate The precise mechanism of action for both drugs is unknown: phentermine is a norepinephrine-dopamine releasing agent; topiramate augments gamma-aminobutyrate (GABA), inhibits α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate glutamate receptors, and inhibits carbonic anhydrase 2012
Saxenda, Victozaa Liraglutide Glucagon-like peptide-1 receptor agonist 2014
Tenuate Dospan Diethylpropion Precise mechanism unknown: norepinephrine-dopamine releasing agent 1959
  1. aApproved for long-term treatment